249 related articles for article (PubMed ID: 25144360)
1. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
4. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.
Pudney VA; Leese AM; Rickinson AB; Hislop AD
J Exp Med; 2005 Feb; 201(3):349-60. PubMed ID: 15684323
[TBL] [Abstract][Full Text] [Related]
5. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
[TBL] [Abstract][Full Text] [Related]
6. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
Long HM; Leese AM; Chagoury OL; Connerty SR; Quarcoopome J; Quinn LL; Shannon-Lowe C; Rickinson AB
J Immunol; 2011 Jul; 187(1):92-101. PubMed ID: 21622860
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
[TBL] [Abstract][Full Text] [Related]
9. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
[TBL] [Abstract][Full Text] [Related]
10. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
Zuo J; Currin A; Griffin BD; Shannon-Lowe C; Thomas WA; Ressing ME; Wiertz EJ; Rowe M
PLoS Pathog; 2009 Jan; 5(1):e1000255. PubMed ID: 19119421
[TBL] [Abstract][Full Text] [Related]
11. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
12. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
14. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.
Griffin BD; Gram AM; Mulder A; Van Leeuwen D; Claas FH; Wang F; Ressing ME; Wiertz E
J Immunol; 2013 Feb; 190(4):1672-84. PubMed ID: 23315076
[TBL] [Abstract][Full Text] [Related]
15. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
[TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.
Gram AM; Oosenbrug T; Lindenbergh MF; Büll C; Comvalius A; Dickson KJ; Wiegant J; Vrolijk H; Lebbink RJ; Wolterbeek R; Adema GJ; Griffioen M; Heemskerk MH; Tscharke DC; Hutt-Fletcher LM; Wiertz EJ; Hoeben RC; Ressing ME
PLoS Pathog; 2016 Apr; 12(4):e1005550. PubMed ID: 27077376
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
18. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
[TBL] [Abstract][Full Text] [Related]
19. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
van Nierop GP; Mautner J; Mitterreiter JG; Hintzen RQ; Verjans GM
Mult Scler; 2016 Mar; 22(3):279-91. PubMed ID: 26041797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
